NAV
$67.09
AUM
$352.9M
Expense Ratio
-
Dividend Yield
0.37%
Beta
0.79
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +19.91% | +17.74% | +23.57% | +63.57% | +19.17% | +6.45% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | OGN | Organon & Co Ordinary Shares | 3.78% |
| 2 | CORT | Corcept Therapeutics Inc | 3.74% |
| 3 | LQDA | Liquidia Corp Ordinary Shares | 2.91% |
| 4 | AXSM | Axsome Therapeutics Inc | 2.67% |
| 5 | DFTX | Definium Therapeutics Inc Ordinary Shares | 2.35% |
| 6 | ELVN | Enliven Therapeutics Inc | 2.34% |
| 7 | JAZZ | Jazz Pharmaceuticals PLC | 2.31% |
| 8 | RPRX | Royalty Pharma PLC Class A | 2.17% |
| 9 | TRVI | Trevi Therapeutics Inc | 2.15% |
| 10 | VTRS | Viatris Inc | 2.11% |
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
Inception Date: 2006-06-19